Lilly Wins EU’s OK for Sepsis Treatment
- Share via
Eli Lilly & Co. said it won European Union approval for Xigris, the first drug designed for a sometimes fatal overreaction to infection known as sepsis.
Lilly won U.S. approval of Xigris last year. First-half Xigris sales were $44.6 million. In April, the Indianapolis-based company cut its 2002 and 2003 profit forecasts, in part because of disappointing sales of Xigris.
Lilly wouldn’t reveal its European sales estimates for Xigris, a company spokeswoman said.
Lilly shares rose 8 cents to $59.65 on the NYSE.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
